Javascript must be enabled to continue!
Towards a survival-based cellular assay for rapid selection of protease inhibitors
View through CrossRef
We are describing a method tailored for in-cell selection of protease
inhibitors. In this method, a target protease is co-expressed with a
selective substrate, the product of which kills the host cells.
Therefore, it can be applied to identify potential inhibitors, based on
cell host survival, when inhibition of the target protease occurs. The
method would be suitable for selection of inhibitors from
intracellularly generated inhibitor libraries, like SICLOPPS, for
instance. TEV protease was chosen for this proof-of-concept. The
genetically encoded selective substrate is a single polypeptide chain,
composed of three parts: (1) ccdB protein that can cause host cell death
when it accumulates inside cell, (2) a protease cleavage sequence, that
can be changed according to the target protease: ENLYFQG sequence for
TEV substrate ( - predicted cleavage site) and (3) the ssrA sequence
(AANDENYALAA), which drives the polypeptide to degradation by the
ClpX/ClpP complex inside host E. coli cells. Conditions for controlled
expression of this substrate, in which its steady-state concentration
did not provoke significant death of host cells, were established.
Co-expression of active TEV protease and this selective substrate
(ccdB-ENLYFQG-ssrA) caused the death of a significant host cell
population, while control assays with an inactive mutant TEV Asp81Asn
did not. Details of the methodology used are given, providing the basis
for the application of similar systems for other proteases of interest.
Title: Towards a survival-based cellular assay for rapid selection of protease inhibitors
Description:
We are describing a method tailored for in-cell selection of protease
inhibitors.
In this method, a target protease is co-expressed with a
selective substrate, the product of which kills the host cells.
Therefore, it can be applied to identify potential inhibitors, based on
cell host survival, when inhibition of the target protease occurs.
The
method would be suitable for selection of inhibitors from
intracellularly generated inhibitor libraries, like SICLOPPS, for
instance.
TEV protease was chosen for this proof-of-concept.
The
genetically encoded selective substrate is a single polypeptide chain,
composed of three parts: (1) ccdB protein that can cause host cell death
when it accumulates inside cell, (2) a protease cleavage sequence, that
can be changed according to the target protease: ENLYFQG sequence for
TEV substrate ( - predicted cleavage site) and (3) the ssrA sequence
(AANDENYALAA), which drives the polypeptide to degradation by the
ClpX/ClpP complex inside host E.
coli cells.
Conditions for controlled
expression of this substrate, in which its steady-state concentration
did not provoke significant death of host cells, were established.
Co-expression of active TEV protease and this selective substrate
(ccdB-ENLYFQG-ssrA) caused the death of a significant host cell
population, while control assays with an inactive mutant TEV Asp81Asn
did not.
Details of the methodology used are given, providing the basis
for the application of similar systems for other proteases of interest.
Related Results
Effects of Dolutegravir and Protease Inhibitors based Regimen on Renal and Liver Function Markers of HIV Patients Attending Daughters of Charity Hospital Abuja
Effects of Dolutegravir and Protease Inhibitors based Regimen on Renal and Liver Function Markers of HIV Patients Attending Daughters of Charity Hospital Abuja
Human immunodeficiency virus (HIV) is a serious public health that has been managed by different HAART regimen for people infected to live a healthier live and also reduce the risk...
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Abstract
Introduction
Tarlatamab is a Delta-like ligand 3 (DLL3) -directed bispecific T-cell engager recently approved for use in patients with advanced small cell lung cancer (SCL...
Presence and partial characterisation of a major proteolytic enzyme in the larval gut of Callosobruchus maculatus
Presence and partial characterisation of a major proteolytic enzyme in the larval gut of Callosobruchus maculatus
AbstractProtease activity in the gut of larvae of the bruchid beetle, Callosobruchus maculatus (a storage pest of cowpea seeds), has been investigated to help clarify nutritional m...
The Potential of Medicinal Plants and Bioactive Compounds in the Fight Against COVID-19
The Potential of Medicinal Plants and Bioactive Compounds in the Fight Against COVID-19
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a novel coronavirus , is causing a serious worldwide COVID-19 pandemic. The emergence of strains with rapid spread and...
Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites
Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites
Two different responses to the therapy were observed in a group of patients receiving the protease inhibitor indinavir. In one, suppression of virus replication occurred and has pe...
Selection Gradients
Selection Gradients
Natural selection and sexual selection are important evolutionary processes that can shape the phenotypic distributions of natural populations and, consequently, a primary goal of ...
Isolation, Screening, Characterization and Identification of Alkaline Protease Producing Bacteria from Leather Industry Effluent
Isolation, Screening, Characterization and Identification of Alkaline Protease Producing Bacteria from Leather Industry Effluent
Abstract
BackgroundA wide variety of Bacterial species produces protease enzyme and the application of same enzyme have been manipulated precisely and used in various biote...
Safety and Efficacy of Atezolizumab in Ovarian Cancer
Safety and Efficacy of Atezolizumab in Ovarian Cancer
Abstract
Introduction
Although the efficacy of PD-L1 blockade has been evaluated in analyses that combine pharmacologically distinct antibodies, the specific efficacy and safety of...

